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Objectives. To examine the feasibility of using milrinone to test
pulmonary vascular reactivity in patients before heart transplan-
tation, we tested the hypothesis that milrinone would lower
pulmonary vascular resistance (PVR) in patients with severe
heart failure.
Background. Fixed pulmonary hypertension is a risk factor for
right heart failure and death after orthotopic heart transplanta-
tion. Sodium nitroprusside, the agent used most commonly to test
for reversibility of pulmonary hypertension before transplanta-
tion, requires dose titration and is frequently limited by hypoten-
sion. Milrinone is an intravenously active phosphodiesterase
inhibitor that acts rapidly and exerts both positive inotropic and
direct vasodilator effects in patients with heart failure. The ability
of milrinone to lower PVR in patients with heart failure has not
been tested.
Methods. In 27 patients with New York Heart Association
functional class III or IV heart failure referred for heart trans-
plantation with a PVR >200 dynes-s-cm
5, we measured the
hemodynamic response to a single intravenous bolus of milrinone
(50 g/kg body weight) infused over 1 min.
Results. Milrinone decreased PVR in all patients. The effect was
maximal 5 to 10 min after the bolus and persisted for at least
20 min. The reduction in PVR at 5 min ([mean  SEM] 31  4%)
was associated with a 42  4% increase in cardiac output and
decreases of 12  4% and 16  5% in mean pulmonary artery and
pulmonary artery wedge pressures, respectively, but no change in
transpulmonary pressure gradient. Milrinone had no effect on
heart rate or systemic arterial pressure. The magnitude of the
decrease in PVR correlated inversely with the milrinone-induced
increase in cardiac output.
Conclusions. Bolus milrinone consistently decreases PVR in
patients with pulmonary hypertension secondary to severe heart
failure. This effect is rapid in onset and well tolerated, even by
patients with low systemic arterial pressure. An intravenous bolus
of milrinone can be used to test for the reversibility of pulmonary
hypertension in patients with heart failure undergoing evaluation
for heart transplantation.
(J Am Coll Cardiol 1996;28:1775–80)
1996 by the American College of Cardiology
Pulmonary vascular resistance (PVR) is frequently elevated in
patients with chronic heart failure, despite conventional med-
ical therapy (1,2). Because ﬁxed pulmonary hypertension is a
risk factor for right heart failure and death after heart trans-
plantation (1,3–5), preoperative pharmacologic assessment of
the reversibility of pulmonary vascular hypertension has be-
come a requisite part of the pretransplantation evaluation. The
ability to lower PVR to 200 dynes-s-cm5 without systemic
hypotension with nitroprusside, the agent most commonly used
to assess pulmonary vascular reactivity before transplantation,
indicates a favorable short-term prognosis (6). However, nitro-
prusside requires careful dose titration, and in many patients
its use is limited by hypotension due to systemic vasodilation
(6). Other agents that have been used to assess pulmonary
vasoreactivity before transplantation include prostaglandin E1
(7), adenosine (8) and inhaled nitric oxide (9–12).
Milrinone is an intravenously active phosphodiesterase
inhibitor that exerts both positive inotropic and direct vasodi-
lator effects (13,14). In patients with severe heart failure, we
previously found (15) that milrinone increased cardiac output
(CO) and reduced systemic vascular resistance (SVR) to a
greater extent than nitroprusside when the agents were given
at rates that caused matched reductions in arterial blood
pressure. This observation suggests that if milrinone is an
effective pulmonary vasodilator, it may be associated with a
smaller decrease in systemic arterial pressure, for a given
decrease in PVR, relative to nitroprusside. However, despite
the clinical use of milrinone for several years, there is almost
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no information available regarding its effect on PVR. The
purpose of the present study was to determine whether milri-
none can be used to test for reversibility of pulmonary vascular
hypertension in patients with heart failure. To examine this
possibility, we tested the hypothesis that milrinone would lower
PVR if administered as a rapid intravenous bolus in patients
with severe heart failure undergoing evaluation for heart
transplantation.
Methods
Study patients. The study included 27 patients (20 men, 7
women; mean [SEM] age 52  2 years, range 36 to 74) with
chronic New York Heart Association functional class III (n 
23) or IV (n  4) heart failure and a PVR 200 dynes-s-cm5
who were referred for consideration for heart transplantation
(n  26) or for management of heart failure (n  1). The
underlying etiology of heart failure was idiopathic dilated
cardiomyopathy in 12 patients, ischemic cardiomyopathy in 12,
rheumatic heart disease in 1, adriamycin toxicity in 1 and
hypertrophic cardiomyopathy in 1. The majority of patients
were receiving digoxin (85%), diuretic drugs (96%), an
angiotensin-converting enzyme inhibitor (93%) and Coumadin
(85%). Other cardiac medications included amiodarone
(19%), hydralazine (7%), nitrates (26%) and beta-adrenergic
antagonists (11%). Left ventricular ejection fraction and end-
diastolic dimension by echocardiography were 0.22  0.02
(range 0.10 to 0.48) and 70  3 mm (range 50 to 100),
respectively. Written informed consent was obtained from all
patients.
Hemodynamic measurements. Digoxin and diuretic and
vasodilator drugs were withheld for at least 12 h before
catheterization. No premedication other than local anesthesia
(1% lidocaine) was used. Right heart catheterization was
performed through the right internal jugular vein or right
femoral vein using a 7F Swan-Ganz catheter (Arrow Interna-
tional, Inc.). Systemic arterial pressure was monitored from a
radial artery cannula or through a 6F sidearm sheath placed in
the right femoral artery (Cordis Laboratories). The electrocar-
diogram, systemic arterial, right atrial (RA), pulmonary artery
(PA) and pulmonary artery wedge (PAW) pressures were
recorded on a strip-chart recorder (Electronics for Medicine,
PPG Biomedical Systems Division). The designation PAW
pressure, as used herein, refers to a PA occluded pressure, as is
typically obtained by inﬂation of the Swan-Ganz catheter
balloon in a distal PA branch. The PA and PAW pressures
were meaned electronically; CO was determined by the Fick
method using the measured oxygen consumption (model
MRM 2B, Waters Instruments, Inc.) and oxygen content in the
PA and systemic arteries. Oxygen content was calculated from
blood hemoglobin and oxygen saturation by standard methods.
Blood oxygen saturation was determined in duplicate samples
(Ciba-Corning model 270 Co-oximeter). Derived hemody-
namic variables were calculated using standard formulas as
follows: Cardiac index (liters/min per m2)  CO/Body surface
area; Transpulmonary pressure gradient (mm Hg)Mean PA
pressure  PAW pressure; SVR (dynes-s-cm5)  80 (Mean
arterial pressure  Mean RA pressure)/CO; PVR (dynes-s-
cm5)  80 (Mean PA pressure  PAW pressure)/CO; and
PVR (Wood U)  (Mean PA pressure  PAW pressure)/CO.
Study protocol. With the patient supine and breathing
room air, baseline hemodynamic data were obtained as the
mean of two sets of measurements separated by at least 10 min
and differing by 10%. Milrinone was administered through a
systemic vein as an intravenous bolus of 50 g/kg body weight
over a period of 1 min. Hemodynamic measurements were
repeated every 5 min for a total of 20 min.
Statistical methods. Results are presented as mean
value  SEM. The hemodynamic effects of milrinone over
time were analyzed by two-way analysis of variance using a
term for patient identiﬁcation and post hoc analysis with the
Student Newman-Keuls test. The SAS statistical package (SAS
Institute) was used for these analyses. Differences between
subgroups were determined by two-tailed unpaired t tests.
Least squares linear regression analysis was used to determine
the relation between various hemodynamic variables and the
magnitude of the PVR response to milrinone. Differences were
considered signiﬁcant if the null hypothesis could be rejected
at the 0.05 probability level.
Results
Baseline hemodynamic variables. Rest hemodynamic vari-
ables (Table 1) revealed moderate to severe heart failure with
elevated right and left heart ﬁlling pressures, a reduced CO
and elevated SVR. Signiﬁcant pulmonary hypertension was
present, with elevated PA pressures, a mean transpulmonary
pressure gradient of 15  1 mm Hg and a mean PVR of 356 
26 dynes-s-cm5.
Hemodynamic response to milrinone. The hemodynamic
effects of a single rapid bolus infusion of milrinone were
maximal at 5 to 10 min after the infusion and persisted for at
least 20 min (Table 1, Fig. 1 to 4). Milrinone decreased the
systolic, diastolic and mean PA pressures (9%, 14% and 12%,
respectively, at 5 min) (Fig. 1). Mean PAW pressure decreased
(16  5% at 5 min) in parallel with the decrease in mean PA
pressure. Consequently, the transpulmonary gradient was un-
changed (Fig. 1). The CO increased by 42  4% at 5 min (Fig.
2). The PVR decreased in parallel with the increase in CO,
with a peak effect at 5 to 10 min (Fig. 3). The PVR decreased
in all but one patient by 5 min (mean decrease 31  4%) (Fig.
Abbreviations and Acronyms
CO  cardiac output
NO  nitric oxide
PA  pulmonary artery
PAW  pulmonary artery wedge
PVR  pulmonary vascular resistance
RA  right atrial
SVR  systemic vascular resistance
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4) and fell below 200 dynes-s-cm5 in 63  9% of the patients
at some time between 5 and 20 min after the infusion. The one
patient in whom PVR increased at 5 min (from 269 to 296
dynes-s-cm5) subsequently had a maximal PVR reduction of
43% at 15 min. Milrinone decreased SVR by 30 3% at 5 min
but had no effect on systolic arterial pressure, RA pressure or
heart rate.
Determinants of PVR response to milrinone. The magni-
tude of the decrease in PVR with milrinone did not correlate
with the baseline mean PA pressure, mean PAW pressure, CO
or PVR (data not shown). The magnitude of change in PVR
with milrinone also did not correlate with the magnitude of the
milrinone-induced decreases in mean PA or PAW pressure
(r  0.29 and r  0.06, respectively). However, the decrease in
PVR correlated inversely with the increase in CO (r  0.48,
p  0.01) (Fig. 5).
To examine further whether the PVR-lowering effect of
milrinone was related to baseline hemodynamic variables or
other hemodynamic effects of milrinone, patients with a
milrinone-induced PVR reduction above and below the me-
dian (43%) were compared. Milrinone decreased PVR 43%
(mean 55  2%) in 14 patients and 43% (mean 25  2%) in
13 patients (Table 2). The two groups did not differ with regard
to baseline PVR or its determinants (mean PA and mean PAW
pressures, CO, transpulmonary pressure gradient), although
the PAW pressure tended to be higher in the more responsive
group. The milrinone-induced changes in mean PA and mean
PAW pressures were similar in the two groups. However, the
more responsive group had a larger milrinone-induced in-
crease in CO (56  5% vs. 40  6%, p  0.04) and decrease
in transpulmonary gradient (34  4% vs. 0  5%, p  0.001).
Discussion
The major new ﬁnding of this study is that milrinone
decreases the PVR in patients with pulmonary vascular hyper-
Figure 1. Effect of a single intravenous bolus of milrinone on PA mean
pressure (squares), PAW pressure (circles) and transpulmonary pres-
sure gradient (triangles) in 27 patients with left ventricular dysfunc-
tion. *p  0.01 versus baseline.
Figure 2. Effect of a single intravenous bolus of milrinone on CO.
*p  0.01 versus baseline.
Table 1. Baseline Hemodynamic Variables and Responses to a Single Intravenous Bolus of Milrinone
Baseline 5 min 10 min 15 min 20 min
PAS (mm Hg) 58  2 53  3* 51  3* 51  3* 50  3*
PAD (mm Hg) 32  1 28  2* 27  2* 27  2* 26  2*
PAM (mm Hg) 40  1 36  2* 35  2* 34  2* 34  2*
PAWP (mm Hg) 25  1 22  2* 21  2* 20  1* 19  2*
TPG (mm Hg) 15  1 14  1 14  1 14  1 14  1
CO (liters/min) 3.6  0.2 5.0  0.3* 4.9  0.3* 4.8  0.3* 4.6  0.3*
CI (liters/min per m2) 1.8  0.1 2.6  0.1* 2.5  0.1* 2.5  0.1* 2.4  0.1*
PVR (dynes-s-cm5) 356  26 242  18* 242  18* 251  21* 266  23*
PVR (Wood U) 4.5  0.3 3.0  0.2* 3.0  0.2* 3.1  0.3* 3.3  0.3*
SAP (mm Hg) 113  3 113  3 111  4 111  4 110  3
DAP (mm Hg) 69  2 63  2* 62  2* 62  2* 62  2*
MAP (mm Hg) 81  2 77  2* 76  2* 75  2* 75  2*
RAP (mm Hg) 13  1 12  1 12  1 12  1 12  1
SVR (dynes-s-cm5) 1,646  115 1,129  80* 1,128  85* 1,144  76* 1,210  87*
HR (beats/min) 84  3 83  3 84  3 84  3 84  3
*p 0.01 versus baseline. Data presented are mean value SEM. CI cardiac index; CO cardiac output; DAP
diastolic arterial pressure; HR heart rate; MAPmean arterial pressure; PAD pulmonary artery diastolic pressure;
PAM  pulmonary artery mean pressure; PAS  pulmonary artery systolic pressure; PAWP  pulmonary artery wedge
pressure; PVR  pulmonary vascular resistance; RAP  right atrial pressure; SAP  systolic arterial pressure; SVR 
systemic vascular resistance; TPG  transpulmonary gradient.
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tension secondary to left ventricular failure. The systemic
hemodynamic effects of milrinone have been well character-
ized in patients with left ventricular failure. Intravenous infu-
sion of milrinone in such patients increases CO and stroke
volume while decreasing left and right heart ﬁlling pressures
and SVR (15–17). Although a decrease in PA pressure has
been noted with milrinone, the effect of milrinone on PVR has
not been studied in detail.
Effect of milrinone on hemodynamic variables and PVR.
We found that the rapid infusion of milrinone as a bolus over
1 min decreased PVR in all patients studied, with a mean
decrease of 31  4% at 5 min. The decrease in PVR occurred
rapidly, with a maximal effect in 5 to 10 min and was sustained
for at least 20 min. Milrinone also decreased SVR, but
systemic arterial pressure was unchanged because of the
increase in CO. Milrinone caused parallel decreases in PA and
PAW pressures and increased CO. Milrinone did not decrease
the transpulmonary pressure gradient, and therefore the de-
crease in PVR was due entirely to the increase in CO.
Likewise, the decrease in PVR correlated with the milrinone-
induced increase in CO but not with changes in PA, PAW or
transpulmonary pressures. Because the transpulmonary gradi-
ent did not increase in the setting of a higher CO, by deﬁnition,
the resistance to pulmonary blood ﬂow (i.e., PVR) decreased.
Mechanism. Themechanism responsible for the milrinone-
induced decrease in PVR is not known. Milrinone is a phos-
phodiesterase inhibitor that appears to act primarily by in-
creasing the levels of cyclic adenosine monophosphate in
myocardial and vascular tissues (18,19). In vivo and in vitro
studies have shown (14,20) that milrinone exerts a direct
relaxant effect on vascular smooth muscle. Thus, milrinone
may have lowered PVR as a result of a direct relaxant effect on
the pulmonary vasculature (21,22). However, the pulmonary
hemodynamic effects of milrinone differ from those of two
other potent direct-acting vasodilators—nitroprusside and ni-
tric oxide (NO)—in patients with heart failure. Nitroprusside
decreases PVR because of both a decrease in transpulmonary
pressure gradient and an increase in CO (23,24). We (9) and
others (10,11) have found that inhaled NO has no effect on CO
or mean PA pressure but decreases the transpulmonary pres-
sure gradient due to an increase in PAW pressure. We propose
that this increase in PAW pressure reﬂects increased left
ventricular venous return due to the decrease in PVR and is
therefore evident in patients with left ventricular failure but
not those with normal left ventricular function.
These observations suggest that milrinone may lower PVR,
Figure 3. Effect of a single intravenous bolus of milrinone on PVR.
*p  0.01 versus baseline.
Figure 4. Plots showing PVR before and 5 min after an intravenous
bolus of milrinone in 27 patients with left ventricular dysfunction. *p
0.0001 versus baseline.
Figure 5. Scatterplot showing the relation between percent change in
PVR and percent change in CO after an intravenous bolus of
milrinone.
Table 2. Baseline Hemodynamic Variables and Response to Milrinone
in Patients With a Milrinone-Induced Decrease in Pulmonary Vascular
Resistance Above or Below the Median
PVR Decrease
43%
(n  14)
PVR Decrease
43%
(n  13) p Value
Baseline PAM (mm Hg) 42 2 38 2 0.25
Baseline PAWP (mm Hg) 27 1 23 2 0.06
Baseline TPG (mm Hg) 14 1 15 1 0.51
Baseline CO (liters/min) 3.4 0.3 3.7 0.3 0.48
Baseline PVR (dynes-s-cm5) 359 42 352 34 0.89
Baseline PVR (Wood U) 4.5 0.5 4.4 0.4 0.89
% Change in
PAM 24 4 15 5 0.16
PAWP 33 6 29 6 0.67
TPG 34 4 0 5  0.001
CO 56 5 40 6 0.04
PVR 55 2 25 2
Data presented are mean value  SEM. Abbreviations as in Table 1.
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at least in part, by a mechanism other than direct pulmonary
vasodilation. In patients with heart failure, milrinone causes
both direct vasodilation and a positive inotropic effect (13,14),
and it has been shown (13,15) that both effects contribute to
the increase in CO. It is well known that the pulmonary
vasculature has the ability to accommodate rapid increases in
blood ﬂow without an increase in the transpulmonary pressure
gradient through the recruitment of parallel vessels (25). In
addition, it is now apparent that an increase in blood ﬂow can
induce vasodilation in several vascular beds, including the
pulmonary vasculature (26,27), by the release of endothelial
cell NO (28–30). Thus, it is possible that the milrinone-
induced decrease in PVR is due, at least in part, to the increase
in CO, which results in a secondary decrease in PVR by
recruitment of accessory vessels or ﬂow-mediated vasodilation,
or both. Coddens et al. (31) have also suggested that the
pulmonary vasodilator effects of nitroprusside and dobutamine
may be secondary to increased pulmonary blood ﬂow.
Pulmonary vascular resistance testing before heart trans-
plantation. Preoperative assessment of pulmonary vascular
reactivity is routinely performed to identify patients with ﬁxed
pulmonary hypertension who are at increased risk for right
heart failure and death after orthotopic heart transplantation
(32,33). Nitroprusside is the agent most commonly used for
this purpose. The response to nitroprusside has been used to
stratify patients into high and low risk groups for postoperative
complications (4,6). A limitation to the use of nitroprusside is
that the systolic arterial pressure falls below 85 mm Hg in
27% of patients and may thereby preclude full assessment of
pulmonary vascular reactivity (6). Several other pharmacologic
agents have been used to test pulmonary vasoreactivity before
transplantation. Prostaglandin E1 has been shown (7) to
decrease the transpulmonary pressure gradient and PVR to a
greater degree than nitroprusside, but like nitroprusside, pros-
taglandin E1 lowered mean arterial pressure to a substantial
degree. As discussed earlier, inhaled NO effectively lowers
PVR in patients with heart failure but does so at the expense
of increasing the left heart ﬁlling pressure (9,10,12). Adenosine
caused a greater decrease in transpulmonary pressure gradient
than nitroprusside without lowering systemic arterial pressure,
but like NO, was limited by its tendency to increase the PAW
pressure (8).
This study demonstrates that milrinone can be used to
rapidly assess pulmonary vascular reactivity during evaluation
for heart transplantation. In this regard, it is noteworthy that
milrinone did not decrease systemic arterial pressure and was
well tolerated, even by patients with a low arterial pressure.
This observation is consistent with previous studies (15–17,34)
that have shown little or no decrease in arterial pressure with
intravenous milrinone. We previously demonstrated that, com-
pared with nitroprusside in the same patients, milrinone
caused a greater increase in CO for any given decrease in SVR
or arterial pressure (15), apparently due to the fact that
milrinone increases CO due to both direct vasodilator and
positive inotropic actions (13). Other attractive features of the
bolus administration of milrinone for the pretransplantation
evaluation of pulmonary vascular reactivity are the simplicity
and rapidity of the test. Whether milrinone has advantages
over other agents used for this purpose, such as nitroprusside
or inhaled NO, remains to be determined. In addition, because
the number of patients studied was small and they were not
followed up after transplantation, no conclusions can be drawn
regarding the predictive value of the milrinone response for
posttransplantation events.
Conclusions. We showed that a single rapid bolus infusion
of milrinone effectively lowers PVR in patients with left
ventricular failure and is well tolerated. This effect may be due
to a direct pulmonary vasodilator effect of the drug or to a
secondary effect due to the increase in CO, or both. These data
suggest that milrinone may be a useful agent for testing
pulmonary vascular reactivity in patients being evaluated for
heart transplantation.
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